Equillium, Inc. EQ

New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulationLA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portug

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A

LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co

40% Sequential Revenue Growth and Record ClearLake Quarter Reflect Growing Momentum Across EQ's Proprietary Platforms TORONTO, ON / ACCESS Newswire / August 20, 2026 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in AI and data-driven ...

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter end

Canadians can now earn card-linked rewards on the everyday purchases that matter most including Fuel, Hotel, Grocery and Health & Beauty TORONTO, ON / ACCESS Newswire / July 21, 2026 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in AI ...

Equillium, Inc. (NASDAQ:EQ), with a year-to-date gain of 89.68% and upside potential of 121.10%, secures a spot on our list of hot biotech stocks under $5 to buy. Two analyst updates landed on the same day, both pointing to growing conviction around the company’s lead asset. On May 28, 2026, Leerink upgraded Equillium, Inc. (NASDAQ:EQ) […]

New capability delivers 90 prebuilt real-time audience segments powered by EQ Works' proprietary data ecosystem, helping marketers move from research to campaign activation up to three times faster TORONTO, ON / ACCESS Newswire / June 4, 2026 / EQ ...

Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ETLA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a virtual investor event on Wednesday, May 27, 2026, at 11:00 AM ET. The event will be presented by Stephen Connelly Ph.D., Equillium’s Chief Scientific Officer, and include new preclinical data evaluating several clinic

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy Cash and cash equivalents expected to fund currently planned operations into 2029 LA JOLLA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology

LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer’s 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. About EquilliumEquillium is a biotech